· PL02.09 Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Gene (ACROSS 2): Phase III study

FLAURA2: Exploratory OS analysis—osimertinib + platinum-pemetrexed in poorer-prognosis EGFR-mutant NSCLC

Beamion LUNG-1 (Phase Ib): Zongertinib first-line in HER2-mutant NSCLC

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial

Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study

NeoADAURA: Neoadjuvant osimertinib in EGFR-mutated early-stage NSCLC.

OptiTROP-Lung04 (Phase III): Sacituzumab tirumotecan (TROP2-ADC) vs platinum chemo after EGFR-TKI

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center

Genomic Profiling of Driver Gene Alterations in Patients With Non–Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients

Panel Discussion: EGFR mutated lung cancer (both sessions)

Sponsored Session: Treatment Evolution of Non-squamous Non-small Cell Lung Cancer

Panel Discussion: Redefining First-Line and Sequencing Strategies in Advanced EGFRm NSCLC

Panel Discussion: Personalizing Immunotherapy in mNSCLC; Tecentriq evidence journey

CRSF Oration & Felicitation: Regulation of Clinical Trials in India: Special Relevance to Oncology Trial and future direction

Advanced Lung Cancer - ALK and ctDNA: PL02.18 Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC

Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study

A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival

Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)

Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non–Small Cell Lung Cancer: An Updated Meta-Analysis

Panel Discussion: Based on the Above Topics

LT Strategies in the Management of ALK+ NSCLC with ALUNBRIG

PANEL DISCUSSION: The ALK Odyssey: Tracing the path from diagnosis to innovation

Panel Discussion: Re-inventing the wheel in NSCLC with Serplulimab: Updates from WCLC and ESMO 2025

Breaking Frontiers in 1L mNSCLC Leveraging Anti PD-1 & Anti CTLA-4 for high unmet need patients

Lighting new hope in ES-SCLC with 6 year reported overall survival

18P: Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing nonsquamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial

Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: update from the LOXO-RAS-20001 trial

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy

Sevabertinib (BAY 2927088) in advanced HER2?mutant NSCLC — SOHO?01 study

ARROS-1 Trial - Zidesamtinib in Advanced ROS1+ NSCLC (WCLC 2025)

Panel Discussion: Based on the Above Topics

Moving the needle for mNSCLC management – focusing on PD-L1 negatives -

Role of amivantamab in the EGFRm NSCLC

PANEL DISCUSSION: From progression to possibilities: transforming management of EGFRm NSCLC

Panel Discussion: the Unresectable Stage III NSCLC Landscape: From PACIFIC to LAURA

Evolving Trends of NewerI/O in management of Cancer in India

RET-Driven Cancers: Evolving Paradigms in precision oncology